Advertisement
Advertisement

U.S. FDA cuts gap for Moderna COVID-19 booster dose to five months

By:
Reuters
Updated: Jan 7, 2022, 14:27 UTC

(Reuters) - The U.S. Food and Drug Administration said on Friday it shortened the interval between the primary series of the Moderna COVID-19 vaccine and a booster dose by a month for people aged 18 or above to at least five months.

SOMOS Community Care administers Moderna COVID-19 vaccine at pop-up site in New York

(Reuters) – The U.S. Food and Drug Administration said on Friday it shortened the interval between the primary series of the Moderna COVID-19 vaccine and a booster dose by a month for people aged 18 or above to at least five months.

“Vaccination is our best defense against COVID-19, including the circulating variants, and shortening the length of time between completion of primary series and a booster dose may help reduce waning immunity,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said.

The move follows the agency’s decision on Monday to reduce the necessary interval to get a booster dose of Pfizer and BioNTech COVID-19 vaccine to five months from six, saying such a change may provide better protection sooner against the fast-spreading Omicron variant.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Did you find this article useful?

Advertisement